This e-presentation offers a critical appraisal of the impact of recent merger and antitrust developments on the pharmaceutical sector. After describing how the CJEU has recently interpreted the concept of excessive pricing, it moves on to explain the consequences of the European Commission’s Guidance on the application of the referral mechanism set out in Article 22 of the Merger Regulation.
e-Presentation | March 2022 | Learning time: 48 minutes
e-Presentation by Nicolas Pourbaix, Senior Counsel, Amgen, Diegem.